SCHEMBL4692273

SCHEMBL4692273

CCOC(=O)C(=O)CC(=O)Cc1ccc(C(C)(C)C)cc1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
LMNA P02545 3/20 0.53
NR1H4 Q96RI1 3/20 0.43
EPHX2 P34913 2/20 0.43
TP53 P04637 2/20 0.43
RORC P51449 1/20 0.42
ESRRB O95718 1/20 0.42
ESRRG P62508 1/20 0.42
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
NLRP3 Q96P20 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7643425 0.88 MAPT (0.55) MAPTSMN1; SMN2LMNANR1H4EPHX2
SCHEMBL24208566 0.87 NPSR1 (0.52) MAPTSMN1; SMN2LMNAEPHX2RORC
SCHEMBL31215066 0.85 MAPT (0.63) MAPTSMN1; SMN2LMNANR1H4EPHX2
SCHEMBL31215065 0.85 MAPT (0.63) MAPTSMN1; SMN2LMNANR1H4EPHX2
SCHEMBL15964600 0.84 KMT2A (0.48) MAPTSMN1; SMN2LMNARAB9AMEN1
SCHEMBL15964601 0.82 KMT2A (0.49) MAPTLMNACYP2C9MEN1KMT2A
SCHEMBL3412717 0.82 MAPT (0.51) MAPTSMN1; SMN2LMNAEPHX2NPC1
SCHEMBL15955979 0.82 MAPT (0.53) MAPTSMN1; SMN2LMNAEPHX2TP53
SCHEMBL1738091 0.81 SMN1; SMN2 (0.48) MAPTSMN1; SMN2MEN1KMT2AL3MBTL1
SCHEMBL12704024 0.81 HTT (0.53) SMN1; SMN2LMNAEPHX2NPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1685113-B1 SUBSTITUTED PYRAZOLES AS PPAR AGONISTS SMITHKLINE BEECHAM CORP (US) 2008-07-30 EP disclosed
EP-1685113-B1 SUBSTITUTED PYRAZOLES AS PPAR AGONISTS SMITHKLINE BEECHAM CORP (US) 2008-07-30 EP disclosed
US-20080021030-A1 Substituted Pyrazoles As Ppar Agonists SMITHKLINE BEECHAM CORPORATION 2008-01-24 US disclosed
US-20080021030-A1 Substituted Pyrazoles As Ppar Agonists SMITHKLINE BEECHAM CORPORATION 2008-01-24 US disclosed
US-20080021030-A1 Substituted Pyrazoles As Ppar Agonists SMITHKLINE BEECHAM CORPORATION 2008-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021030-A1 Substituted Pyrazoles As Ppar Agonists PPARD, PPARA, PPARG MAPT 4679/4885SMN1; SMN2 3739/4885LMNA 3984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.